.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,011,050

« Back to Dashboard

Details for Patent: 6,011,050

Title: Substituted phenethylsulfones and method of reducing TNF.alpha. levels
Abstract:Phenethylsulfones substituted in the position .alpha. to the phenyl group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the levels of TNF.alpha. in a mammal. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline- 1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline- 1,3-dione.
Inventor(s): Muller; George W. (Bridgewater, NJ), Man; Hon-Wah (Neshanic Station, NJ)
Assignee: Celgene Corporation (Warren, NJ)
Filing Date:Jun 29, 1999
Application Number:09/340,617
Claims:1. A sulfone selected from the group consisting of

(a) a compound of the formula: ##STR4## in which: the carbon atom designated * constitutes a center of chirality;

Y isSO.sub.2 ;

each of R.sup.1, R.sup.2, R.sup.3, and R.sup.4, independently of the others, is hydrogen, halo, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano, hydroxy, or --NR.sup.8 R.sup.9 ; or any two of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 on adjacent carbon atoms, together with the depicted phenylene ring are naphthylidene

each of R.sup.5 and R.sup.6, independently of the other, is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, cyano, or cycloalkoxy of up to 18 carbon atoms;

R.sup.7 is hydroxy, alkyl of 1 to 8 carbon atoms, phenyl, benzyl, or --NR.sup.8' R.sup.9' ; each of R.sup.8 and R.sup.9 taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R.sup.8 and R.sup.9 is hydrogen and the other is --COR.sup.10, or --SO.sub.2 R.sup.10, or R.sup.8 and R.sup.9 taken together are tetramethylene, pentamethylene, hexamethylene, or --CH.sub.2 CH.sub.2 X'CH.sub.2 --CH.sub.2 -- in which X.sup.1 is --O--, --S-- or --NH--; and

each of R.sup.8' and R.sup.9' taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R.sup.8' and R.sup.9' is hydrogen and the other is --COR.sup.10', or --SO.sub.2 R.sup.10', or R.sup.8' and R.sup.9' taken together are tetramethylene, pentamethylene, hexamethylene, or --CH.sub.2 CH.sub.2 X.sup.2 CH.sub.2 CH.sub.2 -- in which X.sup.2 is --O--, --S-- or --NH--;

R.sup.10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and

R.sup.10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and

(b) the acid addition salts of said compounds which contain a nitrogen atom susceptible of protonation.

2. A sulfone according to claim 1 wherein in said compound, each of R.sup.1, R.sup.2, R.sup.3, and R.sup.4, independently of the others, is hydrogen, halo, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, or --NR.sup.8 R.sup.9 in which each of R.sup.8 and R.sup.9 taken independently of the other is hydrogen or methyl, or one of R.sup.8 and R.sup.9 is hydrogen and the other is --COCH.sub.3.

3. A sulfone according to claim 1 wherein in said compound, one of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is --NH.sub.2 and the remaining of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are hydrogen.

4. A sulfone according to claim 1 wherein in said compound, one of R.sup.1, R.sup.2, R3, and R.sup.4 is --NHCOCH.sub.3 and the remaining of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are hydrogen.

5. A sulfone according to claim 1 wherein in said compound, one of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is methyl or ethyl and the remaining of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are hydrogen.

6. A sulfone according to claim 1 wherein in said compound, one of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is fluoro and the remaining of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are hydrogen.

7. A sulfone according to claim 1 wherein in said compound, one of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 is --N(CH.sub.3).sub.2 and the remaining of R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are hydrogen.

8. A sulfone according to claim 1 wherein in said compound, each of R.sup.5 and R.sup.6, independently of the other, is hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopentoxy, or cyclohexoxy.

9. A sulfone according to claim 1 wherein in said compound, R.sup.5 is alkoxy and R.sup.6 is alkoxy, cycloalkoxy, or bicycloalkoxy.

10. A sulfone according to claim 1 wherein in said compound, R.sup.5 is methoxy and R.sup.6 is ethoxy.

11. A sulfone according to claim 1 wherein in said compound, R.sup.7 is hydroxy, methyl, ethyl, phenyl, benzyl, or NR.sup.8' R.sup.9' in which each of R.sup.8 ' and R.sup.9 ' taken independently of the other is hydrogen or methyl.

12. A sulfone according to claim 1 wherein in said compound, R.sup.7 is methyl.

13. A sulfone according to claim 1 wherein in said compound, R.sup.7 is NR.sup.8' R.sup.9' in which each of R.sup.8' and R.sup.9' taken independently of the other is hydrogen or methyl.

14. A pharmaceutical composition comprising a quantity of a compound according to claim 1 sufficient upon administration in a single or multiple dose regimen to reduce levels of TNF.alpha. in a mammal in combination with a carrier.

15. The method of reducing undesirable levels of TNF.alpha. in a mammal which comprises administering thereto an effective amount of a compound according to claim 1.

16. The method of inhibiting PDE IV in a mammal which comprises administering thereto an effective amount of a compound according to claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc